Follistatin (FST-344)

What Is Follistatin?

Follistatin is a binding protein that regulates members of the TGF-beta superfamily, especially activin and myostatin.

The FST-344 label is commonly used in research-peptide discussions, though follistatin biology includes multiple isoforms and complex tissue-specific functions.

Its strongest popular association is muscle growth because myostatin is a negative regulator of muscle mass.

On Peptidelogy, Follistatin is organized as a research reference rather than a consumer product page. The most useful way to read the entry is to separate chemical identity, proposed mechanism, study context, safety observations, and unresolved questions.

This matters because many peptide topics are discussed online with a mix of laboratory data, clinical studies, anecdotal claims, and supplier language. A reliable reference keeps those categories separate so readers can see what has actually been studied and what remains speculative.

What Does Follistatin Do?

Research discussions of Follistatin usually center on myostatin inhibition, muscle hypertrophy models, activin biology. In practice, that means studies look for measurable changes in defined biological pathways, tissue models, biomarkers, or clinical endpoints, depending on the compound.

The important distinction is that a studied effect is not the same as a recommendation or guaranteed outcome. Cell-culture findings, animal-model findings, and human trial findings carry different levels of evidence and cannot be treated interchangeably.

Mechanism of Action

Follistatin binds myostatin and activin, limiting their ability to activate downstream receptors. Myostatin inhibition reduces a brake on muscle growth in animal and cellular models.

The same broad binding biology means follistatin can affect reproductive, endocrine, and fibrosis-related pathways as well as skeletal muscle.

Mechanistic explanations are useful because they show why researchers are interested in Follistatin, but they should not be read as proof of real-world efficacy. A plausible pathway still requires well-designed experiments, appropriate controls, reproducible results, and safety evaluation.

Research & Studied Effects

Evidence interpretation

When reviewing studies on Follistatin, the study population or model is central. Findings from rodents, isolated cells, cosmetic panels, endocrine challenge tests, or late-stage clinical trials answer different questions. Stronger pages and citations make that context visible rather than flattening all research into a single claim.

The most reliable summaries also distinguish direct evidence on Follistatin from evidence on related peptides, parent hormones, blend components, or broader drug classes. That distinction is especially important for combination blends and non-peptide compounds that are commonly grouped beside peptides online.

Dosage Information (Research Reference)

Follistatin dosing discussions in public forums are not equivalent to validated clinical protocols.

Research literature includes animal studies, protein exposure, and gene-transfer approaches rather than a single standardized dosing model.

Administration and reconstitution context

Some public pages discuss reconstitution, vial concentration, and route of administration. Peptidelogy does not turn those discussions into instructions. Where those details appear in literature, they are treated as study-method information tied to a specific protocol, not a general template.

Any dose reported for Follistatin should be interpreted alongside route, species, participant criteria, duration, outcome measures, and safety monitoring. Removing those details can make a research dose look more broadly applicable than it is.

Side Effects & Safety Profile

• Human safety profile for non-approved follistatin use is not established.
• Because follistatin affects activin and related pathways, endocrine and tissue-remodeling effects are theoretical concerns.

Safety summaries for Follistatin are limited by the quality and maturity of the evidence. A compound with promising mechanistic data may still have unknown risks, and a compound studied clinically may still have indication-specific warnings, contraindications, or monitoring requirements.

Research Quality Notes

Reference pages in this category often include quality, handling, and source-vetting discussions. For Peptidelogy, those ideas are rewritten as research-quality cautions: identity, purity, storage stability, sterility where relevant, and documentation all affect whether a study can be interpreted reliably.

For defined peptides, useful documentation may include sequence confirmation, molecular-weight verification, batch-specific purity testing, and contaminant screening. For blends or branded formulation topics, the first question is whether the ingredient composition is standardized enough to compare one study or claim with another.

This section is not purchasing guidance and does not endorse any supplier. It is included because poor identity control, degradation, contamination, or unclear formulation can undermine research interpretation and create safety uncertainty.

Frequently Asked Questions

Follistatin vs IGF-1 LR3

Related Peptides

References

1. Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proceedings of the National Academy of Sciences. 2001;98(16):9306-9311.
2. Haidet AM, Rizo L, Handy C, et al. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proceedings of the National Academy of Sciences. 2008;105(11):4318-4322.
3. Matzuk MM, Lu N, Vogel H, et al. Multiple defects and perinatal death in mice deficient in follistatin. Nature. 1995;374:360-363.